Pacific Biosciences of California, Inc.

NasdaqGS:PACB Stock Report

Market Cap: US$482.7m

Pacific Biosciences of California Management

Management criteria checks 2/4

Pacific Biosciences of California's CEO is Christian O. Henry, appointed in Sep 2020, has a tenure of 4.42 years. total yearly compensation is $8.05M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $637.09K. The average tenure of the management team and the board of directors is 4.3 years and 12 years respectively.

Key information

Christian O. Henry

Chief executive officer

US$8.0m

Total compensation

CEO salary percentage8.6%
CEO tenure4.4yrs
CEO ownership0.1%
Management average tenure4.3yrs
Board average tenure12yrs

Recent management updates

Recent updates

Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 93% Above Its Share Price

Dec 10
Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 93% Above Its Share Price

Pacific Biosciences' Cost Cuts Won't Offset Rising Competition

Nov 12

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Nov 07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Rockets 56% But Many Are Still Ignoring The Company

Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Oct 16
Health Check: How Prudently Does Pacific Biosciences of California (NASDAQ:PACB) Use Debt?

Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Sep 20
Even With A 37% Surge, Cautious Investors Are Not Rewarding Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Performance Completely

Pacific Biosciences: A Speculative Play On Long-Read Genomics Sequencing

Aug 21

Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

Jul 02
Take Care Before Jumping Onto Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even Though It's 33% Cheaper

We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Jun 08
We Think Pacific Biosciences of California (NASDAQ:PACB) Has A Fair Chunk Of Debt

Pacific Biosciences: Navigating Rough Waters In Gene Sequencing Seas

Jun 03

These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

Apr 25
These Analysts Think Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Sales Are Under Threat

It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Apr 16
It's Down 25% But Pacific Biosciences of California, Inc. (NASDAQ:PACB) Could Be Riskier Than It Looks

Pacific Biosciences' Pivot: From Shareholder Dilution To Expansion And Leadership

Mar 19

Pacific Biosciences: Strong Cash And Doubling Revenue Signal Investment Growth

Feb 08

With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

Feb 01
With A 34% Price Drop For Pacific Biosciences of California, Inc. (NASDAQ:PACB) You'll Still Get What You Pay For

What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Dec 18
What You Can Learn From Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S

Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

Nov 13
Does Pacific Biosciences of California (NASDAQ:PACB) Have A Healthy Balance Sheet?

The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Aug 28
The Price Is Right For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Even After Diving 27%

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Jul 31
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Trading At A 32% Discount?

Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Jul 06
Is It Time To Consider Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

May 25
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt

Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Mar 29
Is Now The Time To Look At Buying Pacific Biosciences of California, Inc. (NASDAQ:PACB)?

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

Feb 26
Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) Worth US$8.8 Based On Its Intrinsic Value?

CEO Compensation Analysis

How has Christian O. Henry's remuneration changed compared to Pacific Biosciences of California's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$394m

Jun 30 2024n/an/a

-US$400m

Mar 31 2024n/an/a

-US$297m

Dec 31 2023US$8mUS$695k

-US$307m

Sep 30 2023n/an/a

-US$309m

Jun 30 2023n/an/a

-US$319m

Mar 31 2023n/an/a

-US$321m

Dec 31 2022US$7mUS$667k

-US$314m

Sep 30 2022n/an/a

-US$299m

Jun 30 2022n/an/a

-US$206m

Mar 31 2022n/an/a

-US$175m

Dec 31 2021US$3mUS$650k

-US$181m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$59m

Dec 31 2020US$13mUS$195k

US$29m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$51m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$100kn/a

-US$84m

Sep 30 2019n/an/a

-US$115m

Jun 30 2019n/an/a

-US$111m

Mar 31 2019n/an/a

-US$109m

Dec 31 2018US$88kn/a

-US$103m

Compensation vs Market: Christian O.'s total compensation ($USD8.05M) is above average for companies of similar size in the US market ($USD2.12M).

Compensation vs Earnings: Christian O.'s compensation has increased whilst the company is unprofitable.


CEO

Christian O. Henry (56 yo)

4.4yrs

Tenure

US$8,046,575

Compensation

Mr. Christian O. Henry, MBA, is Independent Director of Ginkgo Bioworks Holdings, Inc. from 2016. He served as Independent Director at CM Life Sciences III Inc. since April 07, 2021 until December 2021. He...


Leadership Team

NamePositionTenureCompensationOwnership
Christian O. Henry
President4.4yrsUS$8.05m0.13%
$ 637.1k
Mark Van Oene
Chief Operating Officer4.1yrsUS$4.60m0.12%
$ 601.5k
Stephen Turner
Co-Founder24.6yrsUS$466.76kno data
Michele Farmer
VP & Chief Accounting Officer3.8yrsno data0.012%
$ 59.4k
Brett Atkins
General Counsel & Corporate Secretaryno datano datano data
Natalie Welch
Chief People Officerno datano datano data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: PACB's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christian O. Henry
President6.6yrsUS$8.05m0.13%
$ 637.1k
William Ericson
Independent Director21.1yrsUS$259.00k0.0064%
$ 30.8k
Lucy Shapiro
Independent Director12.4yrsUS$255.00k0%
$ 0
John Milligan
Independent Chairman11.6yrsUS$297.00k0.037%
$ 180.4k
Harry Gray
Member of the Scientific Advisory Boardno datano datano data
Joseph Bonventre
Member of the Scientific Advisory Boardno datano datano data
Randall Livingston
Independent Director16.1yrsUS$265.00k0%
$ 0
Harold Craighead
Member of the Scientific Advisory Boardno datano datano data
Roger Kornberg
Member of the Scientific Advisory Boardno datano datano data
Watt Webb
Member of the Scientific Advisory Boardno datano datano data
Kenneth Johnson
Member of the Scientific Advisory Boardno datano datano data
Jay Shendure
Chairman of Scientific Advisory Board2.3yrsno datano data

12.0yrs

Average Tenure

70yo

Average Age

Experienced Board: PACB's board of directors are seasoned and experienced ( 12 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 05:12
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pacific Biosciences of California, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Kyle MiksonCanaccord Genuity
Bryan BrokmeierCantor Fitzgerald & Co.